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SUMMARY
A succession of antimalarial drugs has been deployed to treat human falciparummalaria but each has, in turn, been nulliﬁed
by the spread of drug resistance. The consensus view has always been that, once present, resistance will inevitably rapidly
increase to 100%. However, recent ﬁeld evidence has shown this is not inevitable, and that drug resistance may initially
spread and then stabilize at relatively low frequencies. It is proposed that intense competition between separate malaria
clones co-infecting the same human can generate complex dynamics capable of explaining this observation. Standard
population genetic analysis conﬁrms this assertion. The dynamics underlying the evolution of antimalarial resistance may
therefore be much more complex than previously realized, and can resolve the apparent paradox between ﬁeld data and the
underlying theory of the evolution of resistance. This explanation is novel and the results are equally applicable to other
parasitic species where multiple infections of the same host are common.
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INTRODUCTION
The protozoan parasite Plasmodium falciparum is
responsible for the most virulent form of human
malaria. It rapidly evolved resistance to the main
ﬁrst-line antimalarial drugs, causing a resurgence
in malaria infections and a substantial number of
additional deaths per year (Trape et al. 1998).
Consequently, massive increases in health budgets
will be required to purchase and deploy more ex-
pensive replacement drugs, currently estimated at 2
to 3 billion US$ per annum for Africa alone (Snow,
Eckert and Teklehaimanot, 2003). Mathematical
models of malaria epidemiology and drug resistance
therefore constitute important tools in guiding
strategies for malaria control (McKenzie, 2000;
McKenzie and Samba, 2004) and the associated
ﬁnancial planning (Coleman et al. 2004; Laxmi-
narayan, 2004; Yeung et al. 2004). These models
consistently predict that once drug resistance arises,
it spreads rapidly to 100% (Curtis and Otoo, 1986;
Cross and Singer, 1991; Dye and Williams, 1997;
Hastings, 1997; Hastings and D’Alessandro, 2000;
Hastings, Watkins and White, 2002) making the
early replacement of failing drugs amatter of urgency
(Watkins, Sibley and Hastings, 2005). Despite this
expectation, recent ﬁeld evidence has shown that
resistance may stabilize at levels well below 100%,
necessitating a re-evaluation of our mathematical
understanding of the process. There are three lines of
evidence for stable resistance levels. The ﬁrst line of
evidence is ﬁeld data showing that resistance to
sulphadoxine/pyrimethamine (SP) in Malawi has
been stable over a period of 4 years, ﬂuctuating
around 20–60% depending on how it is measured
(Plowe et al. 2004b). The second line of evidence is
that parasitological resistance to chloroquine (CQ)
ﬂuctuated seasonally around a stable equilibrium
value of approximately 40% over an 8-year period in
Eastern Sudan (Babiker et al. 2005). The third line
of evidence is that geographically adjacent areas in
Tanzania have greatly diﬀering frequencies of alleles
in dhfr and dhps, the genes encoding resistance to SP
(Pearce et al. 2003). It is therefore important for
eﬀective public health planning to fully understand
why resistance appears not to have irrevocably
spread to 100%, and to assess the implications for
future deployments of novel antimalarial drugs and
drug combinations (World Health Organization,
2000, 2001).
One plausible explanation, not previously con-
sidered but explored here, results from the fact that
P. falciparum populations are highly subdivided into
individual human hosts (Arnot, 1998;Anderson et al.
2000). Consequently, the magnitudes of three of the
key forces already known to drive drug resistance
vary with the frequency of resistance, as shown in the
examples of Fig. 1 (the technical derivation of this
ﬁgure is described later). The ﬁrst force is intrahost
selection which arises because individual human
hosts may contain several independently acquired,
genetically distinct malaria infections, or ‘clones’, at
any one time; the number will depend on local
transmission intensity but is typically between 1 and
7 clones per human (Arnot, 1998). Competition
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between clones in a human occurs for transmission
via the mosquito vector (Hastings, 1997; Hastings
and D’Alessandro, 2000) so drug treatment kills
drug-sensitive malaria clones thereby beneﬁting the
surviving drug-resistant clones which dominate
subsequent transmissions from that treated host
(Hastings, 2003; de Rood et al. 2004). Put simply, the
resistant clones ‘expand’ to take the place of the
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Fig. 1. The selective forces* that determine the spread of resistance under two models are shown in parts (A) and (C)
as a function of the frequency of drug resistance in the malaria population. The selection pressures acting on a mutation
encoding resistance are: intrahost selection increasing its transmission from drug-treated humans, natural selection
reducing its genetic ﬁtness in untreated humans and, in the second model, sexual recombination reducing the
probability that the resistant gene combination survives transmission through the mosquito vector. These selective
forces combine to determine the overall net selection coeﬃcient acting against drug-resistant malaria which is shown in
(B) and (D), again as a function of the frequency of resistance. The selection coeﬃcient is deﬁned as the expected
change in resistance frequency per parasite generation. Stable frequencies of resistance therefore occur when the
selection coeﬃcient equals zero: frequencies below this value are associated with positive selective coeﬃcients acting to
increase the frequency of resistance towards its equilibrium level, while frequencies above this value incur negative
selection coeﬃcients which reduce the frequency of resistance back towards the stable equilibrium. Illustrative results
from both models are shown, whose underlying parameters and assumptions are as follows.
Model 1. 10% of human infections are treated by drug, clonal multiplicity (i.e. the number of malaria infections per
human host (Arnot, 1998)) is 2, and the nominal decrease in the ﬁtness of parasites carrying the drug-resistant mutation
is 25%, leading to ﬁtness varying from 85% when frequency of resistance is low, to 100% when frequency is high.
Model 2. 20% of human infections are treated by drug, the nominal decrease in the ﬁtness of parasites carrying the
drug-resistant mutation is 40%, two unlinked genes are required to encode resistance, and human clonal multiplicity
follows a truncated Poisson distribution with mean clonal multiplicity of 2.5, and a maximum clonal multiplicity of 7.
* Intrahost selection is the expected number of additional transmissions that accrue to a resistant clone when co-infecting
drug-sensitive parasites are killed by drug treatment. Fitness is the genetic ﬁtness of the drug-resistant parasites in
untreated humans, expressed as a proportion of the ﬁtness of the drug-sensitive forms. Survives recombination is the
proportion of the progeny of resistant parasites that inherit the drug-resistant genetic combination despite the actions of
genetic recombination during the sexual stage of their life-cycle. Their values are indicated on the (unlabelled) Y-axis.
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sensitive clones killed by drug treatment. Critically,
the magnitude of this beneﬁt depends on the fre-
quency of drug resistance: when resistance is rare the
beneﬁt is high because most co-infecting clones are
drug sensitive and are removed by drug treatment
giving resistant clones a substantial transmission
advantage. However, as resistance spreads, more and
more of the co-infecting clones are drug resistant so
are not eliminated by drug treatment and the beneﬁt
of intrahost selection to any single resistant clone
consequently declines. The second force is natural
selection. Mutations encoding drug resistance are
presumed to pay a penalty through altering parasite
physiology away from a putative evolutionary-
optimal state, reducing the genetic ‘ﬁtness’ of the
mutation in the absence of the drug (Koella, 1998;
Walliker, Hunt and Babiker, 2005; Hastings and
Donnelly, 2005) ; this penalty may be substantial
in haploid organisms such as P. falciparum
(Sirawaraporn et al. 1997). When resistance is rare,
most resistant clones will be in competition with
‘ﬁtter ’ non-mutated drug-sensitive clones co-
infecting the same human, and the genetic costs of
resistance may be substantial. As resistance spreads,
more competition will be with other, equally unﬁt,
resistant clones so the genetic cost will be less
apparent. The third force is genetic recombination.
Drug resistance may require a combination of
mutations in two or more genes. These drug-resist-
ant combinations can be broken apart by genetic
recombination with drug-sensitive genotypes during
the obligate sexual phase of the falciparum life-cycle,
resulting in their progeny being drug sensitive
(Curtis and Otoo, 1986; Dye and Williams, 1997;
Hastings, 1997; Hastings and D’Alessandro, 2000).
As the frequency of resistance increases, more sexual
recombination will be with other resistant clones, so
resistance is more likely to survive recombination
(Fig. 1C). Combinations of mutations may be
required to encode resistance to a single drug (such as
may occur for chloroquine (Hastings, 2003; Talisuna
et al. 2003)), or if drugs are deployed as combination
therapies to deliberately take advantage of this eﬀect;
the latter strategy is now regarded as mandatory by
theWHO (WorldHealth Organization, 2001). It will
be shown that these changes in the magnitude of the
three forces driving resistance can result in stable
levels of resistance.
METHODS
The verbal argument needs to be quantiﬁed to
conﬁrm that stability may occur under plausible
epidemiological circumstances, and it is relatively
straightforward to investigate the interplay between
these forces using standard population genetic
methodology. Two diﬀerent illustrative models are
investigated. A simple case, where resistance is en-
coded by a single gene and all human hosts have the
same number of clones, serves to demonstrate the
basic dynamics using simple algebra. The second
model is more biologically realistic, and hence
algebraically much more complex and intractable,
but demonstrates the generality of the results.
The following symbols are employed in the
methodology:
c is the number of concurrent malaria clones per
human host, or clonal multiplicity;
s is the strength of natural selection acting against
the mutation in the absence of the drug;
f is the frequency of the drug-resistant mutation or
genotype;
d is drug treatment rate, deﬁned as the proportion
of infections treated.
These basic parameters allow the following to be
derived:
Su is the ﬁtness of the drug-sensitive allele(s) in
untreated humans;
Ru is the ﬁtness of the resistant allele(s) in
untreated humans;
Sd is the ﬁtness of the drug-sensitive allele(s)
in drug-treated humans;
Rd is the ﬁtness of the resistant allele(s)
in drug-treated humans.
Model 1: Resistance is encoded by a single gene,
clonal multiplicity is a constant, natural selection
acts independently against the mutation
Natural selection pressures are assumed to be
mediated through competition between mutant and
non-mutant malaria clones co-infecting the same
host*. The proportion of transmissions by a given
clone from any single host is therefore
1
1+(cx1)[f (1xs)+(1xf)]
for sensitive clones, and
1xs
(1xs)+(cx1)[f (1xs)+(1xf )]
for resistant clones
The numerator is the ﬁtness of the sensitive or
resistant clone and the denominator is the expected
mean ﬁtness of the clones within a host. The ﬁrst
component of the denominator is the ﬁtness of the
clone (sensitive or resistant) being considered, and
the second component is the expectedmean ﬁtness of
the remaining cx1 clones in the host (Hastings,
1997).
These equations give the proportion of trans-
missions from the host that any given resistant or
sensitive clone will contribute. Each host makes on
average ‘c ’ transmissions so these proportions must
* Natural selection can also take a constant value
irrespective of co-infecting clones and this can also result in
stable frequencies of resistance; results are not shown.
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be multiplied by c to give the ﬁtness for each clone in
the absence of the drug i.e.
Su=
c
1+(cx1)[f (1xs)+(1xf )]
Ru=
(1xs)c
(1xs)+(cx1)[f(1xs)+(1xf )]
Furthermore:
Sd=0; because the drug sensitive form is killed by
drug treatment.
Rd=1+ (cx1)(1xf )1+(cx1)f ; the second term represents
intrahost selection, the numerator representing the
total number of additional transmissions expected by
a resistant clone as a consequence of drug-sensitive
parasite clones in the same human being eliminated,
and the denominator divides them out between the
resistant clones in that individual. This enables the
average ﬁtness of the resistant and sensitive alleles to
be calculated as
Rr=dRd+(1xd)Ru and Sr=dSd+(1xd)Su,
respectively, allowing the relative ﬁtness of resistance
to be calculated as
R=
Rr
fRr+(1xf)Sr
:
Model 2. Resistance is encoded by two physically
unlinked genes and there is a distribution of clonal
multiplicities within people
This two-gene model is the simplest situation where
genetic combinations are required to encode drug
resistance (Curtis and Otoo, 1986; Dye and
Williams, 1997; Hastings, 1997). Tracking resist-
ance under these circumstances is conceptually
simple although it requires unwieldy equations that
must be solved numerically. The fate of drug
resistance is followed by investigating all possible
combinations of human infection types, and deter-
mining the malaria genotypes transmitted from each
type. Two physically-unlinked genes, A and B en-
code resistance, so there are 4 genotypes in total :AB,
Ab, aB and ab. Following the convention of Dye and
Williams (1997), the lower case represents the
resistance mutations so ab is resistant and all other
genotypes are sensitive to the drug mixture. It is
necessary to track all 4 genotypes because the chance
of losing resistance through recombination depends
on the genotypes of the other clones in the human.
These other clones also determine the intensity
of natural selection. This level of complexitymeans it
is easiest to consider each type of human host, and to
track the genotypes they transmit. Computationally :
fh
0=
P
c=1
Pc
i=0
Pcxi
j=0
Pcxixj
k=0
P1
d=0 p(c)p(i, j, k, l)p(d)t(h)
W
where:
fhk is the frequency of genotype h transmitted to
the next malaria generation; h=1, 2, 3, 4 corre-
sponding to the 4 genotype frequencies,
c is, as before, the number of malaria clones in a
human,
i is the number of AB clones in that host, which
varies from 0 to c,
j is the number of Ab clones in that host, which
varies from 0 to c–i,
k is the number of aB clones in that host, which
varies from 0 to c–i–j,
l is the number of ab clones in that host, which
equals c–i–j–k,
d is drug treatment 0=absent, 1=present,
p(c) is the proportion of humans with c clones.
The distribution of clones per individual is
assumed to follow a Poisson distribution but, for
mathematical convenience and biological realism, we
truncate the distribution at a maximum of 7 clones.
Hosts predicted to havemore than 7 clones are placed
in the c=7 class. In the case of conditional mean of
2.5 (as used in Fig. 1) the frequencies of people with
1, 2, 3 … clones are f(1)=0.27, f(2)=0.30, f(3)=
0.23, f(4)=0.12, f(5)=0.056, f(6)=0.021, f(7)=
0.009 which appears realistic enough for the current
illustrative purposes.
p(i, j,k, l) is the probability of getting this com-
bination of i, j, k, l clones, calculated from the
multinomial distribution using genotype frequencies
in the current malaria generation, p(d) is the prob-
ability of receiving the treatment regimen (i.e. drug-
treated or untreated), t(h) is the proportion of
transmissions from this type of host that are of clone
genotype h.
There will be 4 equations of this type for h=1, 2, 3,
4 and W is a normalization coeﬃcient equal to the
sum of their numerators. Although complex, the
equations are conceptually simple. Summation over c
ensures each of the clonalmultiplicities present in the
population are examined, while summation over i,
j, k simply serves to ensure all possible genotype
combinations within this clonal multiplicity are in-
vestigated.
In drug-treated individuals, t(1)=t(2)=t(3)=0,
because none of these genotypes can survive drug
treatment, and t(4)=1 provided lo1 (i.e. at least 1
resistant genotype is present) else t(4)=0 if l=0
(because no resistant genotypes are present). The
algorithm for calculating t(h) in untreated hosts is a
2-stage process incorporating both natural selection
and recombination. The relative ﬁtnesses of the
genotypes are AB=1, Ab=aB=1xs, ab=(1xs)2,
so frequencies within a human host after natural
selection are:
f hAB=
i
W
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f hAb=
j(1xs)
W
fhaB=
k(1xs)
W
fhab=
l(1xs)2
W
where, as before, W is a normalization coeﬃcient
equal to the sum of their numerators. The resulting
genotypes transmitted after natural selection and
recombination (noting that malaria parasites can
self-fertilize) are:
t(AB)=(f hAB)
2+2f hAB f
h
Ab05+2f hAB fhaB05
+2f hAB f
h
ab05(1xr)+2f hAb fhaB05r
t(Ab)=(f hAb)
2+2f hAB f
h
Ab05+2f hAB fhab05r
+2fhAb f
h
aB05(1xr)+2f hAb fhab05
t(aB)=(fhaB)
2+2f hAB f
h
aB05+2f hAB fhab05r
+2f hAb f
h
aB05(1xr)+2f haB fhab05
t(ab)=(f hab)
2+2f hAB f
h
ab05(1xr)
+2f hAb f
h
aB05r+2fhAb fhab05+2fhaB fhab05
where recombination rate between the genes is r. The
equations were solved numerically and intermediate
calculations were made to calculate the magnitude of
intrahost selection, genetic ﬁtness, and recombi-
national loss.
Intensity of parasite infection often follows a
negative binomial distribution (Crofton, 1971) rather
than a Poisson, so some simulations were also run
with the number of clones per individual assumed to
follow a negative binomial distribution with a con-
ditional mean of 2.5, dispersal coeﬃcient, k, equal to
1.0 and truncated at a maximum of 7 clones per
individual, or with a negative binomial with con-
ditional mean of 2.5, k=0.75 and truncated at 10
clones per individual. The proportions of people in
each class were as follows: f(1)=0.18, f(2)=0.25,
f(3)=0.24, f(4)=0.17, f(5)=0.09, f(6)=0.04, f(7)=
0.03 for k=1.0 and f(1)=0.41, f(2)=0.23, f(3)=0.14,
f(4)=0.08, f(5)=0.05, f(6)=0.03, f(7)=0.02, f(8)=
0.01, f(9)=0.008, f(10)=0.01 for k=0.75.
The model was investigated by setting the
frequency of resistance mutations to be low, and in
linkage equilibrium, and running the equations to
investigate whether resistance is lost, reaches 100%,
or stabilizes at an intermediate frequency. The pro-
cess is repeated with resistance present at very high
frequencies to check that the same result is obtained
(in some instances there is a lower, unstable equi-
librium that must be exceeded before resistance can
spread (Hastings, 1997)). The calculations were
made in Maple v9 (Maplesoft, Waterloo, Ontario), a
specialist algebraic and numeric simulation package.
RESULTS
Examples from the 2 diﬀerent models are shown on
Fig. 1. Parts (A) and (C) show that the forces driving
drug resistance work in opposite directions, and
change in magnitude as the frequency of resistance
increases. These separate forces determine the cor-
responding total, or net, force acting against mu-
tations conferring drug resistance which are shown
on parts (B) and (D). At low frequencies of resistance
the net force is positive so frequency increases, while
at higher frequencies the net force is negative so
frequency is reduced. This leads to a stable fre-
quency of resistance when the net force is zero, as
indicated on the graphs.
The illustrative simulations for Model 2 shown on
Fig. 1C and D were re-run using the truncated
negative binomial distributions. The equilibrium
frequency fell to 0.21 when k=1.0 (but increased to
0.43 if ﬁtness was altered to 35%). Using a distri-
bution with k=0.75, truncated at a maximum of 10
clones per individual, tipped the balance of forces in
favour of drug pressure and resistance spread to
100%; however, if the decrease in drug ﬁtness was
altered to 45%, then the system re-equilibrated at
an intermediate frequency of resistance of 0.29.
Quantitative changes did therefore occur as the dis-
tributions of clones per host were altered, but the
qualitative results were unchanged and the results
appear robust.
DISCUSSION
It therefore appears plausible that, under certain
conditions, resistance can spread and reach stable
frequencies well below 100% but it is not clear how
commonly this occurs. Three lines of evidence were
identiﬁed in the Introduction section. The ﬁrst line
of evidence was the observation by Plowe and col-
leagues that SP resistance had stabilized in Malawi
(Plowe et al. 2004b) which was an unexpected result,
with important clinical implications (Plowe et al.
2004a ; Ringwald, 2004; White, 2004) ; this type of
direct observation is fairly robust. The second line of
evidence, that frequencies ﬂuctuate seasonally
around a long-term equilibrium, is also fairly robust.
Many non-specialists make the mistake of assuming
that ﬂuctuating opposite selection pressures, for ex-
ample favouring resistance in the wet season while
eliminating it in the dry season, will inevitably lead to
a stable, long-term equilibrium. This is not the case.
Standard population genetic analysis suggests that
oscillations will occur but around a trend leading
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towards ﬁxation or loss of the allele determined by its
ﬁtness averaged over the two seasons. An exception
to this behaviour occurs if frequency-dependent
selection is operating, so that the larger the ﬂuctu-
ation from the equilibrium, the larger the selective
force pushing it back towards equilibrium. This is
precisely the type of selection operating in these
models: Fig. 1B, and particularly Fig. 1D, show that
the larger the deviation from the stable equilibrium,
the larger the selection coeﬃcient acting to return it
(although the decline in selective coeﬃcients at very
high frequencies suggests very large ﬂuctuations may
be less easily regulated). It is interesting that the
Babiker et al. data set terminated in 1993, and sub-
sequently there was a signiﬁcant long-term increase
in alleles pfcrtK76T and pfmdr1N86Y that encode
resistance to CQ. Babiker et al. (2005) attributed this
to changing patterns of drug use and this may rep-
resent the situation, discussed below,where one force
(drug use in this case) becomes dominant, upsetting
the balance of forces maintaining the equilibrium
shown on Fig. 1A and C and drives resistance to loss
or ﬁxation. It is important to note that both these
lines of evidence showing long-term stability of
resistance require longitudinal data sets that are not
generally available in most malaria-endemic regions.
Antimalarial resistance could have stabilized in some
areas but passed unnoticed until being eventually
swamped by sustained immigration or changes in
patterns of drug use. The third line of evidence, that
frequencies of resistance vary widely within a small
geographical area, is easier to obtain but is not so
robust as temporal stability. In principle, the dif-
ferences could be due to chance ﬂuctuation in fre-
quencies, or diﬀerences in time since resistance
arrived in the study sites (migration is an important
driver of antimalarial drug resistance in Africa
(Anderson and Roper, 2005)), or diﬀerences in the
rate at which resistance spread locally, but the
intuition of ﬁeld workers is that the diﬀerences are so
large, and occur over such small distances, that none
of these explanations are entirely satisfactory.
Stable frequencies of resistance therefore do
appear to occur in the ﬁeld, so the next consideration
is how good the current model is at explaining this
phenomenon. Strong forces of drug pressure and
natural selection (discussed below) may lead to
relatively large net selection forces stabilizing the
frequency of resistance as illustrated on Fig. 1B
and D. Extensive investigation of the models using
other parameter values revealed that stability is not
inevitable and, as might be expected intuitively, is
dependent on the forces being suﬃciently matched
that they cancel each other out at some intermediate
frequency. In other epidemiological settings, one of
the forces dominates the others irrespective of the
frequency of resistance and determines the fate of
resistance. So, for any given locality, drug pressure
may be suﬃciently high that resistance is spreading
towards ﬁxation (Curtis and Otoo, 1986; Cross and
Singer, 1991; Dye and Williams, 1997; Hastings,
1997; Hastings and D’Alessandro, 2000; Hastings
et al. 2002; Koella and Antia, 2003), or drug use may
be so low that natural selection acting against the
mutation is driving it to elimination (Koella and
Antia, 2003), or the forces may have reached a bal-
ance with strong selection coeﬃcients stabilizing
local frequency as described here. Thus the dynamics
underlying the evolution of antimalarial drug resist-
ance are likely to be much more complex than pre-
viously anticipated. The key factor for public health
policy is the existence of areas where the forces acting
on antimalarial resistance interact to stabilize resist-
ance (as in Fig. 1) that may stabilize the frequency of
resistance over larger geographical areas. This pro-
vides a plausible explanation for the empirical ob-
servations of stable resistance frequencies (Plowe
et al. 2004b ; Babiker et al. 2005) with considerable
local variation in these frequencies (Pearce et al.
2003). The inevitable question arises about whether
this eﬀect could have a diﬀerential impact in areas of
high and low malaria transmission, and contribute to
their putative diﬀerences in the epidemiology of drug
resistance. This is a complex subject, reviewed else-
where (Hastings and Watkins, 2005), but the most
likely scenario is that areas of stable frequencies are
more likely to arise in regions of higher transmission
where extensive multiclonal infections can generate
the dynamics illustrated on Fig. 1. It is possible to
conjecture that the presence of sites equilibrating the
frequency of resistance may impede the overall
spread of resistance, but a formal analysis is outside
the scope of the present study and would have to be
placed in the much broader context of metapopu-
lation dynamics (see Ariey, Duchemin and Robert
(2003) for an excellent review of this approach).
There appears to be only one other theoretical
study predicting stable frequencies of resistance, that
of Koella and Antia (2003). Their study utilized a
metapopulation approach where the total parasite
population is assumed to be strongly subdivided into
semi-isolated populations. If resistance is strongly
favoured in some populations, while being strongly
eliminated in others, then a stable equilibrium
frequency can occur. This arises because disfavoured
alleles will persist transiently in a population between
their time of immigration and eventual elimination;
this is the migration/selection balance of standard
population genetics. The practical drawback of this
approach is that selective diﬀerences have to be very
large and/or migration rates very low for this balance
to occur else migration overwhelms the eﬀect of
selection (see discussion by Ariey et al. (2003)).
Koella and Antia (2003) presented results based on
the assumption that drug coverage of infections is
100% in some areas and 0% in others. Such diﬀer-
ences in drug use are unlikely in the African context,
especially where presumptive drug use is high, and
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the high levels of gene ﬂow between putative African
subpopulations makes this explanation less attractive
in an African setting; this is not to say this expla-
nation cannot be valid but, as noted by Ariey et al.
(2003), most malaria populations in Africa are likely
to be panmictic, and the metapopulation approach is
more applicable to areas such as Asia and S. America
where transmission is generally less intense andmore
heterogeneous.*
Models are only valid if their underlying assump-
tions are met. Unfortunately, the assumptions are
often implicit and hidden in the technical derivation
of the model and it is vital to make these explicit. The
critical assumption made here is that human infec-
tivity is not changed by the number of clones and
type of parasites they harbour, nor the type of
treatment they receive; the exception being drug-
treated humans infected only with drug-sensitive
parasites whose infectivity is zero. This does not
imply that all humans are equally infective, simply
that no systematic diﬀerences in infectivity occur so
that, for example, a drug-treated individual with 1
resistant and 1 sensitive clone is as infective as a non-
treated human with 3 sensitive clones. This has two
implications, one quantitative, the other qualitative.
The quantitative implication is that this paradigm
may not be strictly met; some drug-sensitive clones
will survive drug treatment when the latter is sub-
optimal, for example if an incorrect dose is taken, the
full course in not taken, pharmacogenetic variation
means the drug is not properly metabolized, and so
on. Similarly, the assumption that drug treatment
has no eﬀect on resistant clones is questionable; most
‘resistant’ infections are reduced by treatment to
quite low levels before recrudescing later. These
assumptions are commonly used in modelling work
(see, for example, Curtis and Otoo (1986), Dye and
Williams (1997), Hastings (1997), Koella and Antia
(2003)), the reasoning being that such details com-
plicate the models and obscure the basic behaviours
of the model system. This is the justiﬁcation used
here, noting that it would be relatively simple to
include these eﬀects in the equations deﬁning the
models. The key, qualitative assumption is of equal
infectivity of hosts so that, for example, people are on
average equally infective irrespective of whether they
contain 1, 2, 3 or 4 clones (the generalized immunity
or ‘GI’ model of Hastings (1997)). The opposite
assumption would be that clones are regulated
independently so that a person with 2 clones is twice
as infective as a person with 1 clone, and only half as
infective as a person with 4 clones (the speciﬁc
immunity or ‘SI’ model of Hastings (1997)) ; the
assumption of GI or SI regulation of infectivity has
fundamental implications for the evolution of
resistance for reasons discussed in more detail else-
where (Hastings, 1997; Hastings and D’Alessandro,
2000; de Rood et al. 2004). There is no deﬁnitive
evidence for or against these diﬀerent models of
regulation. It seems plausible that the total number
of malaria parasites may be regulated by host
responses such as acquired immunity and/or fever,
but the sexual transmission stages constitute only a
very small proportion of this total (about 5%) so in-
dividual clones may well be able to independently
regulate their infectivity. However, even if this type
of SI regulation does occur in humans, it may be
nulliﬁed by GI regulation in subsequent stages, for
example if only a limited number of sporozoites can
colonize the mosquito salivary glands. There is some
indirect evidence favouring GI. The epidemiology of
CQ resistance is best explained using a GI model
(Hastings, 2003; Talisuna et al. 2003) and a GI
model ﬁts observations made on P. chabaudi infect-
ing laboratory mice (although the latter needs to be
interpreted with extreme caution because chabaudi
is, obviously, a diﬀerent species from falciparum, and
also because mice are not its natural host and it dis-
plays diﬀerent infection dynamics to that which
occur in its natural host (Taylor-Robinson, 1995)).
So GI regulation is likely, but it should be made
explicit that the model and results presented here
rely critically on an assumption of GI. If SI regu-
lation does occur, the intrahost dynamics shown in
Fig. 1A and C will not arise, and the model should be
regarded as invalid.
The models used parameters that have been well
characterized in ﬁeld studies of malaria epidemi-
ology. The number of clones per individual is
routinely measured at microsatellite or other highly
variable genetic loci, and found to range from around
1 up to 7 per person (Anderson et al. 2000; Arnot,
1998), with a mean in high transmission areas of
around 3 (Arnot, 1998). These are almost certainly
underestimates : the numbers of parasites within a
clone ﬂuctuates over time and molecular methods
routinely fail to detect the presence of ‘minority’
clones which are obscured by the numerically
dominant clones present at the time of sampling.
A recent analysis concluded that 50% of clones are
missed for this reason, and that the mean number
of clones is closer to 7 in an area of moderately
high transmission (Sama et al. 2005). The analyses
described here assumed a lower average number of
clones. This was a conservative assumption because
if a larger number of clones are present then intrahost
dynamics operates over a wider range. For example,
if there are 7 clones in a host it varies from 0 to
approximately 6 according to the frequency of
* Koella and Antia (2003) also predicted that stable
equilibrium frequencies of resistance could exist in a single
population as a consequence of superinfection. However,
the epidemiological, rather than population genetic,
formulation of this process caused problems allowing, for
example, a deleterious resistant mutation to invade even if
no drug was being deployed and the results need to be
interpreted with extreme caution (Hastings, 2004a).
Dynamics of drug-resistant malaria 621
resistance compared, for example, to the range of 0 to
2.2 shown in Fig. 1C where mean clonal multiplicity
is 2.5. A wider range of values gives more oppor-
tunity for the forces to cancel out at some inter-
mediate frequency leading to a stable equilibrium.
Assuming a relatively low number of clones
demonstrates that the conclusions are robust and can
occur even in areas where mean clonal multiplicity
may be relatively low. A related question is the dis-
tribution of number of clones around this mean, here
assumed to be a truncated Poisson. In reality we have
no real estimate for this distribution. The number of
bites per individual can vary substantially over even
small distances (Smith et al. 1995) but whether this
results in a negative binomial distribution in the
number of clones per individual and what force(s), if
any, limit the number of clones per individual, is a
matter of conjecture. The same qualitative results
arise when using Poisson or negative binomial dis-
tributions, or even if all people have the same number
of clones, so the conclusions appear robust to the type
of distribution used to describe the number of clones
per individual. Genetic recombination between these
clones can be directly observed in oocysts obtained
from mosquito gut walls which contain the products
of the obligate sexual phase of the life-cycle (Ranford-
Cartwright et al. 1991; Paul et al. 1995), allowing the
probability that a resistant gene combination survives
recombination to be directly calculated. Natural
selection pressures against resistance mutations may
be relatively large, evidence coming from the rare
origin of resistance to the widely used antimalarials
chloroquine (Wootton et al. 2002) and SP (Cortese
et al. 2002; Nair et al. 2003; Hastings, 2004b ; Roper
et al. 2004, 2003) the rapid decline in the frequencies
of mutations responsible for chloroquine resistance
once drug pressure is removed (Kublin et al. 2003;
Mita et al. 2003), and the known reduction in enzyme
catalytic activity associated with mutations in the
dhfr gene encoding pyrimethamine resistance
(Sirawaraporn et al. 1997) ; these lines of evidence are
discussed further elsewhere (Hastings and Donnelly,
2005). These studies investigated point mutations in
dhfr, dhps and pfcrt but recent evidence has suggested
that changes in the copy number of pfmdr1 may be
important in encoding resistance to meﬂoquine
(Price et al. 2004). The same principles apply, and
selection pressures may plausibly be larger because
of physical problems of chromosome matching dur-
ing recombination, and because unequal crossing
over may regenerate the original, single-copy hap-
lotype (which is mathematically equivalent to natural
selection in this model).
It is reassuring that ﬁeld observations can now be
reconciled with theory, because it implies there are
no major problems with our theoretical under-
standing of theway drug resistance spreads (although
it is important to note that we cannot prove the above
explanation is the true, or even the primary reason,
simply that it is plausible and consistent with the
data ; other, currently unidentiﬁed factors, may also
exist that cause stable frequencies). The penalty paid
for this greater understanding is an increase in the
complexities of the equations describing the spread
of resistance. The equations describing spread in
earlier models are far simpler and easy to understand
(Dye and Williams, 1997; Hastings, 1997; Hastings
et al. 2002), so it is probably best to use this earlier
work to gain a qualitative, intuitive understanding of
the dynamics underlying resistance, and to use the
more complex approach described here inModel 2 to
gain additional insights into speciﬁc aspects of the
dynamics of antimalarial drug resistance.
The results have wider implications for many
other micro-parasitic infections. Helminth parasites
frequently exhibit intense intrahost competition and
selection, a phenomenon known as the ‘crowding’
eﬀect (Anderson and May, 1992) equivalent to the
GI regulation described above; their sexual life-cycle
means that recombinational loss of resistance gene
combinations will occur; and the mechanisms of
drug action and parasite resistance suggest that ﬁt-
ness costs will plausibly be associated with resistance
(Wolstenholme et al. 2004).Drug resistance is amajor
concern in human microscopic helminth infections
such as schistosomiasis (Coles et al. 1987; Doenhoﬀ
et al. 2002; Hagan et al. 2004) and onchocerciasis
(Dadzie, Neira and Hopkins, 2003; Awadzi et al.
2004). The incorporation of the complex dynamics,
identiﬁed above, caused by intrahost eﬀects may
therefore be usefully incorporated into these dis-
cussions and have a wider impact on our under-
standing of drug resistance in other important
human infections. The spread of antimicrobial drug
resistance in parasitic species which are highly sub-
divided into, and compete within, separate hosts are
likely to be very diﬀerent from the dynamics of drug
resistance in large, randomly-breeding populations.
Recognition of this fact, and its consequences, is
likely to provide a signiﬁcant advance in under-
standing how drug resistance evolves in such species,
with important consequences for the treatment of
many human diseases.
I thank two anonymous reviewers for many helpful
comments on the manuscript.
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